{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,15]],"date-time":"2026-11-15T10:53:33Z","timestamp":1794740013418,"version":"4.9.1"},"reference-count":89,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T00:00:00Z","timestamp":1789689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T00:00:00Z","timestamp":1789689600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["APP2009577"],"award-info":[{"award-number":["APP2009577"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"name":"The University of Queensland","id":[{"id":"https:\/\/ror.org\/00rqy9422","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Diabetologia"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims\/hypothesis<\/jats:title>\n                    <jats:p>Menopause hormone therapy (MHT) may have effects on metabolic conditions. This study was conducted to systematically review the literature, to summarise and quantify the effect of MHT on glucose or insulin levels and on new-onset type 2 diabetes among women without type 2 diabetes and to summarise and quantify the effect of MHT on glucose, insulin, lipid and blood pressure levels among women with type 2 diabetes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Data from six electronic databases (PubMed, Embase, Cochrane, CINAHL, PsyclNFO and MEDLINE) from inception to 29 July 2025 were searched for randomised controlled trials (RCTs) and cohort studies comparing MHT users with non-users among postmenopausal women or women undergoing the menopausal transition. Eligible studies reported the effects of MHT on glucose metabolism, lipid levels or blood pressure in women with or without type 2 diabetes. The risk of bias in RCTs and cohort studies was assessed with version 2 of the Cochrane risk-of-bias for randomised trials (RoB 2) tool and the Risk of Bias in Non-randomised Studies of Interventions (ROBINS-I) tool, respectively. Certainty of evidence (CoE) was assessed with the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach. Random-effects models were used to estimate the pooled effects.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      In total, 49 articles (33 reporting on RCTs and 16 on cohort studies) from 15 countries were identified, involving 1,472,277 participants. The study durations ranged from 1 week to 13.2 years for RCTs and from 6 months to 17 years for cohort studies. Seven of these were assessed as having a low risk of bias. Among women without type 2 diabetes, MHT use was associated with small reductions in fasting insulin (11 studies:\n                      <jats:italic>N<\/jats:italic>\n                      =4262, mean difference [MD] \u22125.90 pmol\/l [95% confidence interval (CI) \u22128.03, \u22123.77 pmol\/l]; high CoE) and in homeostasis model assessment of insulin resistance score (four studies:\n                      <jats:italic>N<\/jats:italic>\n                      =2883, MD \u22120.21 [95% CI \u22120.32, \u22120.09]; moderate CoE), as well as a lower risk of new-onset type 2 diabetes (14 studies:\n                      <jats:italic>N<\/jats:italic>\n                      =1,450,134, risk ratio 0.83 [95% CI 0.75, 0.92]; very low CoE], compared with non-MHT users. Among women with type 2 diabetes, MHT was associated with small reductions in fasting plasma glucose (16 studies:\n                      <jats:italic>N<\/jats:italic>\n                      =1379, MD \u22121.07 mmol\/l [95% CI \u22121.86, \u22120.28 mmol\/l]; very low CoE), haemoglobin A\n                      <jats:sub>1c<\/jats:sub>\n                      (17 studies:\n                      <jats:italic>N<\/jats:italic>\n                      =15,720, MD \u22125.47 mmol\/mol [\u22120.50%] [95% CI \u22128.32, \u22122.62 mmol\/mol (\u22120.76, \u22120.24%)]; very low CoE), cholesterol (15 studies:\n                      <jats:italic>N<\/jats:italic>\n                      =907, MD \u22120.37 mmol\/l [95% CI \u22120.50, \u22120.24 mmol\/l]; low CoE), low-density lipoprotein cholesterol (16 studies:\n                      <jats:italic>N<\/jats:italic>\n                      =961, MD \u22120.33 mmol\/l [95% CI \u22120.54, \u22120.13 mmol\/l]; low CoE) and systolic blood pressure (nine studies:\n                      <jats:italic>N<\/jats:italic>\n                      =630, MD \u22123.43 mmHg (\u22120.46 kPa) [95% CI \u22124.88, \u22121.98 mmHg]; low CoE), compared with non-MHT users.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions\/interpretation<\/jats:title>\n                    <jats:p>MHT showed small beneficial associations with glucose metabolism among women with and without type 2 diabetes, while the effect size was generally too small to be clinically significant. Future studies are needed to shed more light on the effect of MHT by initiation age. Study limitations include the predominantly single-reviewer screening and assessment, the high risk of bias of the included studies and restricted geographical representation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Registration<\/jats:title>\n                    <jats:p>The study protocol was registered with the International Prospective Register of Systematic Reviews (PROSPERO; CRD420251230387).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Funding<\/jats:title>\n                    <jats:p>This work was supported by a National Health and Medical Research Council investigator grant (APP2009577).<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00125-026-06856-6","type":"journal-article","created":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T11:12:59Z","timestamp":1789729979000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Menopause hormone therapy and type 2 diabetes risk and prognosis: systematic review and meta-analyses"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0023-1066","authenticated-orcid":false,"given":"Chen","family":"Liang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4956-0124","authenticated-orcid":false,"given":"Annette J.","family":"Dobson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4024-9308","authenticated-orcid":false,"given":"Jenny","family":"Doust","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2358-1894","authenticated-orcid":false,"given":"Leticia Watanabe","family":"Ribeiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9610-5904","authenticated-orcid":false,"given":"Gita D.","family":"Mishra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,18]]},"reference":[{"issue":"5","key":"6856_CR1","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1001\/jama.2022.24140","volume":"329","author":"CJ Crandall","year":"2023","unstructured":"Crandall CJ, Mehta JM, Manson JE (2023) Management of menopausal symptoms: a review. JAMA 329(5):405\u2013420. https:\/\/doi.org\/10.1001\/jama.2022.24140","journal-title":"JAMA"},{"key":"6856_CR2","unstructured":"Institute for Health Metrics and Evaluation (2023) Global Burden of Disease Compare - interactive data visuals. Available from https:\/\/vizhub.healthdata.org\/gbd-compare\/. Accessed 16\/11\/2025"},{"issue":"10397","key":"6856_CR3","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/S0140-6736(23)01301-6","volume":"402","author":"GBD 2021 Diabetes Collaborators","year":"2023","unstructured":"GBD 2021 Diabetes Collaborators (2023) Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: a systematic analysis for the Global Burden of Disease Study 2021. Lancet 402(10397):203\u2013234. https:\/\/doi.org\/10.1016\/S0140-6736(23)01301-6","journal-title":"Lancet"},{"issue":"6","key":"6856_CR4","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/S2213-8587(21)00269-2","volume":"10","author":"RA Lobo","year":"2022","unstructured":"Lobo RA, Gompel A (2022) Management of menopause: a view towards prevention. Lancet Diabetes Endocrinol 10(6):457\u2013470. https:\/\/doi.org\/10.1016\/S2213-8587(21)00269-2","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"8","key":"6856_CR5","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1097\/GME.0000000000000171","volume":"21","author":"GC Herber-Gast","year":"2014","unstructured":"Herber-Gast GC, Mishra GD (2014) Early severe vasomotor menopausal symptoms are associated with diabetes. Menopause 21(8):855\u2013860. https:\/\/doi.org\/10.1097\/GME.0000000000000171","journal-title":"Menopause"},{"issue":"5","key":"6856_CR6","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1097\/GME.0000000000001033","volume":"25","author":"KE Gray","year":"2018","unstructured":"Gray KE, Katon JG, LeBlanc ES et al (2018) Vasomotor symptom characteristics: are they risk factors for incident diabetes? Menopause 25(5):520\u2013530. https:\/\/doi.org\/10.1097\/GME.0000000000001033","journal-title":"Menopause"},{"issue":"10","key":"6856_CR7","doi-asserted-by":"publisher","first-page":"e2443546","DOI":"10.1001\/jamanetworkopen.2024.43546","volume":"7","author":"MM Hedderson","year":"2024","unstructured":"Hedderson MM, Liu EF, Lee C et al (2024) Vasomotor symptom trajectories and risk of incident diabetes. JAMA Netw Open 7(10):e2443546. https:\/\/doi.org\/10.1001\/jamanetworkopen.2024.43546","journal-title":"JAMA Netw Open"},{"issue":"10","key":"6856_CR8","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1038\/s41574-022-00708-0","volume":"18","author":"I Lambrinoudaki","year":"2022","unstructured":"Lambrinoudaki I, Paschou SA, Armeni E, Goulis DG (2022) The interplay between diabetes mellitus and menopause: clinical implications. Nat Rev Endocrinol 18(10):608\u2013622. https:\/\/doi.org\/10.1038\/s41574-022-00708-0","journal-title":"Nat Rev Endocrinol"},{"issue":"5","key":"6856_CR9","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1111\/j.1463-1326.2005.00545.x","volume":"8","author":"SR Salpeter","year":"2006","unstructured":"Salpeter SR, Walsh JM, Ormiston TM, Greyber E, Buckley NS, Salpeter EE (2006) Meta-analysis: effect of hormone-replacement therapy on components of the metabolic syndrome in postmenopausal women. Diabetes Obes Metab 8(5):538\u2013554. https:\/\/doi.org\/10.1111\/j.1463-1326.2005.00545.x","journal-title":"Diabetes Obes Metab"},{"issue":"10","key":"6856_CR10","doi-asserted-by":"publisher","first-page":"1866","DOI":"10.2337\/dc23-0451","volume":"46","author":"EM Speksnijder","year":"2023","unstructured":"Speksnijder EM, Noever Ten, de Brauw GV, et al (2023) Effect of postmenopausal hormone therapy on glucose regulation in women with type 1 or type 2 diabetes: a systematic review and meta-analysis. Diabetes Care 46(10):1866\u20131875. https:\/\/doi.org\/10.2337\/dc23-0451","journal-title":"Diabetes Care"},{"key":"6856_CR11","doi-asserted-by":"publisher","unstructured":"Li T, Jiang NS, Kaskey J, Schnatz PF, Nudy M (2025) Hormone therapy and insulin resistance in non-diabetic postmenopausal women: a systematic review and meta-analysis. Climacteric\u00a028(6):673\u2013681. https:\/\/doi.org\/10.1080\/13697137.2025.2509844","DOI":"10.1080\/13697137.2025.2509844"},{"key":"6856_CR12","unstructured":"Veritas Health Innovation (2025) Covidence systematic review software. Available from https:\/\/www.covidence.org\/. Accessed 16\/11\/2025"},{"key":"6856_CR13","unstructured":"Sterne JAC, Hernan MA, McAleenan A, Reeves BC, Higgins JPT (2024) Chapter 25: assessing risk of bias in a non-randomized study. Available from https:\/\/www.cochrane.org\/authors\/handbooks-and-manuals\/handbook\/current\/chapter-25. Accessed 16\/11\/2025"},{"key":"6856_CR14","unstructured":"Higgins JPT, Savovic J, Page MJ, Elbers RG, Sterne JAC (2025) Chapter 8: assessing risk of bias in a randomized trial. Available from https:\/\/www.cochrane.org\/authors\/handbooks-and-manuals\/handbook\/current\/chapter-08. Accessed 16\/11\/2025"},{"key":"6856_CR15","unstructured":"Higgins JPT, Eldridge S, Li T (2025) Chapter 23: including variants on randomized trials. Available from https:\/\/www.cochrane.org\/authors\/handbooks-and-manuals\/handbook\/current\/chapter-23. Accessed 16\/11\/2025"},{"key":"6856_CR16","doi-asserted-by":"publisher","first-page":"e081903","DOI":"10.1136\/bmj-2024-081903","volume":"389","author":"G Guyatt","year":"2025","unstructured":"Guyatt G, Agoritsas T, Brignardello-Petersen R et al (2025) Core GRADE 1: overview of the Core GRADE approach. BMJ 389:e081903. https:\/\/doi.org\/10.1136\/bmj-2024-081903","journal-title":"BMJ"},{"key":"6856_CR17","doi-asserted-by":"publisher","unstructured":"Sedgwick P (2014) Relative risks versus odds ratios. BMJ 348:g1407. https:\/\/doi.org\/10.1136\/bmj.g1407","DOI":"10.1136\/bmj.g1407"},{"issue":"19","key":"6856_CR18","doi-asserted-by":"publisher","first-page":"1690","DOI":"10.1001\/jama.280.19.1690","volume":"280","author":"J Zhang","year":"1998","unstructured":"Zhang J, Yu KF (1998) What\u2019s the relative risk? A method of correcting the odds ratio in cohort studies of common outcomes. JAMA 280(19):1690\u20131691. https:\/\/doi.org\/10.1001\/jama.280.19.1690","journal-title":"JAMA"},{"issue":"6","key":"6856_CR19","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1007\/s10654-025-01250-9","volume":"40","author":"E Dumas","year":"2025","unstructured":"Dumas E, Stensrud MJ (2025) How hazard ratios can mislead and why it matters in practice. Eur J Epidemiol 40(6):603\u2013609. https:\/\/doi.org\/10.1007\/s10654-025-01250-9","journal-title":"Eur J Epidemiol"},{"issue":"5","key":"6856_CR20","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1016\/1047-2797(92)90011-e","volume":"2","author":"JE Manson","year":"1992","unstructured":"Manson JE, Rimm EB, Colditz GA et al (1992) A prospective study of postmenopausal estrogen therapy and subsequent incidence of non-insulin-dependent diabetes mellitus. Ann Epidemiol 2(5):665\u2013673. https:\/\/doi.org\/10.1016\/1047-2797(92)90011-e","journal-title":"Ann Epidemiol"},{"issue":"2","key":"6856_CR21","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1210\/jcem.82.2.3746","volume":"82","author":"B Andersson","year":"1997","unstructured":"Andersson B, Mattsson LA, Hahn L et al (1997) Estrogen replacement therapy decreases hyperandrogenicity and improves glucose homeostasis and plasma lipids in postmenopausal women with noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 82(2):638\u2013643. https:\/\/doi.org\/10.1210\/jcem.82.2.3746","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"6856_CR22","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1007\/s001250050758","volume":"40","author":"HE Brussaard","year":"1997","unstructured":"Brussaard HE, Gevers Leuven JA, Frolich M, Kluft C, Krans HM (1997) Short-term oestrogen replacement therapy improves insulin resistance, lipids and fibrinolysis in postmenopausal women with NIDDM. Diabetologia 40(7):843\u2013849. https:\/\/doi.org\/10.1007\/s001250050758","journal-title":"Diabetologia"},{"issue":"3","key":"6856_CR23","doi-asserted-by":"publisher","first-page":"443","DOI":"10.2105\/ajph.87.3.443","volume":"87","author":"LL Gabal","year":"1997","unstructured":"Gabal LL, Goodman-Gruen D, Barrett-Connor E (1997) The effect of postmenopausal estrogen therapy on the risk of non-insulin-dependent diabetes mellitus. Am J Public Health 87(3):443\u2013445. https:\/\/doi.org\/10.2105\/ajph.87.3.443","journal-title":"Am J Public Health"},{"issue":"10","key":"6856_CR24","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.2337\/diacare.21.10.1589","volume":"21","author":"MA Espeland","year":"1998","unstructured":"Espeland MA, Hogan PE, Fineberg SE et al (1998) Effect of postmenopausal hormone therapy on glucose and insulin concentrations. PEPI Investigators. Postmenopausal Estrogen\/Progestin Interventions. Diabetes Care 21(10):1589\u20131595. https:\/\/doi.org\/10.2337\/diacare.21.10.1589","journal-title":"Diabetes Care"},{"issue":"12","key":"6856_CR25","doi-asserted-by":"publisher","first-page":"1984","DOI":"10.2337\/diacare.22.12.1984","volume":"22","author":"BE Klein","year":"1999","unstructured":"Klein BE, Klein R, Moss SE (1999) Exogenous estrogen exposures and changes in diabetic retinopathy. The Wisconsin Epidemiologic Study of Diabetic Retinopathy. Diabetes Care 22(12):1984\u20131987. https:\/\/doi.org\/10.2337\/diacare.22.12.1984","journal-title":"Diabetes Care"},{"issue":"2","key":"6856_CR26","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1097\/00001721-199903000-00004","volume":"10","author":"L Hahn","year":"1999","unstructured":"Hahn L, Mattsson LA, Andersson B, Tengborn L (1999) The effects of oestrogen replacement therapy on haemostatic variables in postmenopausal women with non-insulin-dependent diabetes mellitus. Blood Coagul Fibrinolysis 10(2):81\u201386. https:\/\/doi.org\/10.1097\/00001721-199903000-00004","journal-title":"Blood Coagul Fibrinolysis"},{"issue":"1","key":"6856_CR27","first-page":"36","volume":"6","author":"R Kimmerle","year":"1999","unstructured":"Kimmerle R, Heinemann L, Heise T et al (1999) Influence of continuous combined estradiol-norethisterone acetate preparations on insulin sensitivity in postmenopausal nondiabetic women. Menopause 6(1):36\u201342","journal-title":"Menopause"},{"issue":"9","key":"6856_CR28","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.2337\/diacare.22.9.1401","volume":"22","author":"K Samaras","year":"1999","unstructured":"Samaras K, Hayward CS, Sullivan D, Kelly RP, Campbell LV (1999) Effects of postmenopausal hormone replacement therapy on central abdominal fat, glycemic control, lipid metabolism, and vascular factors in type 2 diabetes: a prospective study. Diabetes Care 22(9):1401\u20131407. https:\/\/doi.org\/10.2337\/diacare.22.9.1401","journal-title":"Diabetes Care"},{"issue":"2","key":"6856_CR29","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/s0378-5122(00)00164-x","volume":"37","author":"C Cornu","year":"2000","unstructured":"Cornu C, Mercier C, Ffrench P et al (2000) Postmenopause hormone treatment in women with NIDDM or impaired glucose tolerance: the MEDIA randomized clinical trial. Maturitas 37(2):95\u2013104. https:\/\/doi.org\/10.1016\/s0378-5122(00)00164-x","journal-title":"Maturitas"},{"issue":"21","key":"6856_CR30","doi-asserted-by":"publisher","first-page":"3315","DOI":"10.1001\/archinte.160.21.3315","volume":"160","author":"MH Davidson","year":"2000","unstructured":"Davidson MH, Maki KC, Marx P et al (2000) Effects of continuous estrogen and estrogen-progestin replacement regimens on cardiovascular risk markers in postmenopausal women. Arch Intern Med 160(21):3315\u20133325. https:\/\/doi.org\/10.1001\/archinte.160.21.3315","journal-title":"Arch Intern Med"},{"issue":"3","key":"6856_CR31","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/s0378-5122(99)00112-7","volume":"34","author":"P Manwaring","year":"2000","unstructured":"Manwaring P, Morfis L, Diamond T, Howes LG (2000) The effects of hormone replacement therapy on plasma lipids in type II diabetes. Maturitas 34(3):239\u2013247. https:\/\/doi.org\/10.1016\/s0378-5122(99)00112-7","journal-title":"Maturitas"},{"issue":"2","key":"6856_CR32","first-page":"137","volume":"3","author":"CA Aguilar-Salinas","year":"2001","unstructured":"Aguilar-Salinas CA, Arita Melzer O, Sauque Reyna L et al (2001) Effects of estrogen\/medrogestone therapy on the apoprotein B-containing lipoproteins in postmenopausal women with type 2 diabetes mellitus under satisfactory and non-satisfactory glycemic control. Isr Med Assoc J 3(2):137\u2013143","journal-title":"Isr Med Assoc J"},{"issue":"3","key":"6856_CR33","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/s0168-8227(01)00297-2","volume":"54","author":"DA Darko","year":"2001","unstructured":"Darko DA, Dornhorst A, Kennedy G, Mandeno RC, Seed M (2001) Glycaemic control and plasma lipoproteins in menopausal women with type 2 diabetes treated with oral and transdermal combined hormone replacement therapy. Diabetes Res Clin Pract 54(3):157\u2013164. https:\/\/doi.org\/10.1016\/s0168-8227(01)00297-2","journal-title":"Diabetes Res Clin Pract"},{"issue":"7","key":"6856_CR34","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.2337\/diacare.24.7.1144","volume":"24","author":"A Ferrara","year":"2001","unstructured":"Ferrara A, Karter AJ, Ackerson LM, Liu JY, Selby JV, Northern California Kaiser Permanente Diabetes Registry (2001) Hormone replacement therapy is associated with better glycemic control in women with type 2 diabetes: the Northern California Kaiser Permanente Diabetes Registry. Diabetes Care 24(7):1144\u20131150. https:\/\/doi.org\/10.2337\/diacare.24.7.1144","journal-title":"Diabetes Care"},{"issue":"1","key":"6856_CR35","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1210\/jcem.86.1.7094","volume":"86","author":"KE Friday","year":"2001","unstructured":"Friday KE, Dong C, Fontenot RU (2001) Conjugated equine estrogen improves glycemic control and blood lipoproteins in postmenopausal women with type 2 diabetes. J Clin Endocrinol Metab 86(1):48\u201352. https:\/\/doi.org\/10.1210\/jcem.86.1.7094","journal-title":"J Clin Endocrinol Metab"},{"issue":"7 Pt 1","key":"6856_CR36","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1016\/s0895-7061(01)01290-0","volume":"14","author":"CS Hayward","year":"2001","unstructured":"Hayward CS, Samaras K, Campbell L, Kelly RP (2001) Effect of combination hormone replacement therapy on ambulatory blood pressure and arterial stiffness in diabetic postmenopausal women. Am J Hypertens 14(7 Pt 1):699\u2013703. https:\/\/doi.org\/10.1016\/s0895-7061(01)01290-0","journal-title":"Am J Hypertens"},{"issue":"5","key":"6856_CR37","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1016\/s0735-1097(01)01566-2","volume":"38","author":"KK Koh","year":"2001","unstructured":"Koh KK, Kang MH, Jin DK et al (2001) Vascular effects of estrogen in type II diabetic postmenopausal women. J Am Coll Cardiol 38(5):1409\u20131415. https:\/\/doi.org\/10.1016\/s0735-1097(01)01566-2","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"6856_CR38","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/s0015-0282(01)01829-5","volume":"76","author":"RA Lobo","year":"2001","unstructured":"Lobo RA, Bush T, Carr BR, Pickar JH (2001) Effects of lower doses of conjugated equine estrogens and medroxyprogesterone acetate on plasma lipids and lipoproteins, coagulation factors, and carbohydrate metabolism. Fertil Steril 76(1):13\u201324. https:\/\/doi.org\/10.1016\/s0015-0282(01)01829-5","journal-title":"Fertil Steril"},{"issue":"3","key":"6856_CR39","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1210\/jcem.86.3.7297","volume":"86","author":"M Perera","year":"2001","unstructured":"Perera M, Sattar N, Petrie JR et al (2001) The effects of transdermal estradiol in combination with oral norethisterone on lipoproteins, coagulation, and endothelial markers in postmenopausal women with type 2 diabetes: a randomized, placebo-controlled study. J Clin Endocrinol Metab 86(3):1140\u20131143. https:\/\/doi.org\/10.1210\/jcem.86.3.7297","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"6856_CR40","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1053\/meta.2001.20201","volume":"50","author":"WH Sutherland","year":"2001","unstructured":"Sutherland WH, Manning PJ, de Jong SA, Allum AR, Jones SD, Williams SM (2001) Hormone-replacement therapy increases serum paraoxonase arylesterase activity in diabetic postmenopausal women. Metabolism 50(3):319\u2013324. https:\/\/doi.org\/10.1053\/meta.2001.20201","journal-title":"Metabolism"},{"issue":"1","key":"6856_CR41","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1097\/00042192-200101000-00006","volume":"8","author":"RJ Walker","year":"2001","unstructured":"Walker RJ, Lewis-Barned NJ, Sutherland WH et al (2001) The effects of sequential combined oral 17beta-estradiol norethisterone acetate on insulin sensitivity and body composition in healthy postmenopausal women: a randomized single blind placebo-controlled study. Menopause 8(1):27\u201332. https:\/\/doi.org\/10.1097\/00042192-200101000-00006","journal-title":"Menopause"},{"issue":"3","key":"6856_CR42","doi-asserted-by":"publisher","first-page":"500","DOI":"10.2337\/diacare.25.3.500","volume":"25","author":"Y Zhang","year":"2002","unstructured":"Zhang Y, Howard BV, Cowan LD et al (2002) The effect of estrogen use on levels of glucose and insulin and the risk of type 2 diabetes in American Indian postmenopausal women: the Strong Heart Study. Diabetes Care 25(3):500\u2013504. https:\/\/doi.org\/10.2337\/diacare.25.3.500","journal-title":"Diabetes Care"},{"issue":"1","key":"6856_CR43","doi-asserted-by":"publisher","first-page":"1","DOI":"10.7326\/0003-4819-138-1-200301070-00005","volume":"138","author":"AM Kanaya","year":"2003","unstructured":"Kanaya AM, Herrington D, Vittinghoff E et al (2003) Glycemic effects of postmenopausal hormone therapy: the Heart and Estrogen\/progestin Replacement Study. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 138(1):1\u20139. https:\/\/doi.org\/10.7326\/0003-4819-138-1-200301070-00005","journal-title":"Ann Intern Med"},{"issue":"6","key":"6856_CR44","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1046\/j.1365-2265.2003.01906.x","volume":"59","author":"J McKenzie","year":"2003","unstructured":"McKenzie J, Jaap AJ, Gallacher S et al (2003) Metabolic, inflammatory and haemostatic effects of a low-dose continuous combined HRT in women with type 2 diabetes: potentially safer with respect to vascular risk? Clin Endocrinol (Oxf) 59(6):682\u2013689. https:\/\/doi.org\/10.1046\/j.1365-2265.2003.01906.x","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"4","key":"6856_CR45","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1177\/000331970305400402","volume":"54","author":"ND Stojanovic","year":"2003","unstructured":"Stojanovic ND, Kwong P, Byrne DJ et al (2003) The effects of transdermal estradiol alone or with cyclical dydrogesterone on markers of cardiovascular disease risk in postmenopausal women with type 2 diabetes: a pilot study. Angiology 54(4):391\u2013399. https:\/\/doi.org\/10.1177\/000331970305400402","journal-title":"Angiology"},{"issue":"9","key":"6856_CR46","doi-asserted-by":"publisher","first-page":"4615","DOI":"10.1210\/jc.2003-031414","volume":"89","author":"SY Honisett","year":"2004","unstructured":"Honisett SY, Stojanovska L, Sudhir K, Kingwell BA, Dawood T, Komesaroff PA (2004) Hormone therapy impairs endothelial function in postmenopausal women with type 2 diabetes mellitus treated with rosiglitazone. J Clin Endocrinol Metab 89(9):4615\u20134619. https:\/\/doi.org\/10.1210\/jc.2003-031414","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"6856_CR47","doi-asserted-by":"publisher","first-page":"82","DOI":"10.3132\/dvdr.2004.012","volume":"1","author":"AF Kernohan","year":"2004","unstructured":"Kernohan AF, Spiers A, Sattar N et al (2004) Effects of low-dose continuous combined HRT on vascular function in women with type 2 diabetes. Diab Vasc Dis Res 1(2):82\u201388. https:\/\/doi.org\/10.3132\/dvdr.2004.012","journal-title":"Diab Vasc Dis Res"},{"issue":"7","key":"6856_CR48","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1007\/s00125-004-1448-x","volume":"47","author":"KL Margolis","year":"2004","unstructured":"Margolis KL, Bonds DE, Rodabough RJ et al (2004) Effect of oestrogen plus progestin on the incidence of diabetes in postmenopausal women: results from the Women\u2019s Health Initiative Hormone Trial. Diabetologia 47(7):1175\u20131187. https:\/\/doi.org\/10.1007\/s00125-004-1448-x","journal-title":"Diabetologia"},{"issue":"3","key":"6856_CR49","doi-asserted-by":"publisher","first-page":"645","DOI":"10.2337\/diacare.27.3.645","volume":"27","author":"R Rossi","year":"2004","unstructured":"Rossi R, Origliani G, Modena MG (2004) Transdermal 17-beta-estradiol and risk of developing type 2 diabetes in a population of healthy, nonobese postmenopausal women. Diabetes Care 27(3):645\u2013649. https:\/\/doi.org\/10.2337\/diacare.27.3.645","journal-title":"Diabetes Care"},{"issue":"1","key":"6856_CR50","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1111\/j.1463-1326.2004.00294.x","volume":"6","author":"AR Scott","year":"2004","unstructured":"Scott AR, Dhindsa P, Forsyth J, Mansell P, Kliofem Study Collaborative Group (2004) Effect of hormone replacement therapy on cardiovascular risk factors in postmenopausal women with diabetes. Diabetes Obes Metab 6(1):16\u201322. https:\/\/doi.org\/10.1111\/j.1463-1326.2004.00294.x","journal-title":"Diabetes Obes Metab"},{"issue":"6","key":"6856_CR51","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1111\/j.1365-2141.2004.04846.x","volume":"124","author":"JC Stevenson","year":"2004","unstructured":"Stevenson JC, Oladipo A, Manassiev N, Whitehead MI, Guilford S, Proudler AJ (2004) Randomized trial of effect of transdermal continuous combined hormone replacement therapy on cardiovascular risk markers. Br J Haematol 124(6):802\u2013808. https:\/\/doi.org\/10.1111\/j.1365-2141.2004.04846.x","journal-title":"Br J Haematol"},{"issue":"2","key":"6856_CR52","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1016\/j.fertnstert.2005.01.131","volume":"84","author":"MA Osmanagaoglu","year":"2005","unstructured":"Osmanagaoglu MA, Osmanagaoglu S, Osmanagaoglu T, Okumus B, Bozkaya H (2005) Effect of different preparations of hormone therapy on lipid and glucose metabolism, coagulation factors, and bone mineral density in overweight and obese postmenopausal women. Fertil Steril 84(2):384\u2013393. https:\/\/doi.org\/10.1016\/j.fertnstert.2005.01.131","journal-title":"Fertil Steril"},{"issue":"3","key":"6856_CR53","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1007\/s00125-005-0096-0","volume":"49","author":"DE Bonds","year":"2006","unstructured":"Bonds DE, Lasser N, Qi L et al (2006) The effect of conjugated equine oestrogen on diabetes incidence: the Women\u2019s Health Initiative randomised trial. Diabetologia 49(3):459\u2013468. https:\/\/doi.org\/10.1007\/s00125-005-0096-0","journal-title":"Diabetologia"},{"issue":"4","key":"6856_CR54","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1016\/j.maturitas.2005.07.008","volume":"53","author":"L Thunell","year":"2006","unstructured":"Thunell L, Andersson B, Glassell M, Mattsson LA (2006) The effect of continuous combined HRT on glucose homeostasis and plasma lipids. A placebo-controlled study in postmenopausal women with type 2 diabetes. Maturitas 53(4):430\u2013438. https:\/\/doi.org\/10.1016\/j.maturitas.2005.07.008","journal-title":"Maturitas"},{"issue":"1","key":"6856_CR55","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1111\/j.1365-2265.2006.02679.x","volume":"66","author":"AF Kernohan","year":"2007","unstructured":"Kernohan AF, Sattar N, Hilditch T et al (2007) Effects of low-dose continuous combined hormone replacement therapy on glucose homeostasis and markers of cardiovascular risk in women with type 2 diabetes. Clin Endocrinol (Oxf) 66(1):27\u201334. https:\/\/doi.org\/10.1111\/j.1365-2265.2006.02679.x","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"6","key":"6856_CR56","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1530\/EJE-09-0151","volume":"160","author":"K Pentti","year":"2009","unstructured":"Pentti K, Tuppurainen MT, Honkanen R et al (2009) Hormone therapy protects from diabetes: the Kuopio osteoporosis risk factor and prevention study. Eur J Endocrinol 160(6):979\u2013983. https:\/\/doi.org\/10.1530\/EJE-09-0151","journal-title":"Eur J Endocrinol"},{"issue":"10","key":"6856_CR57","doi-asserted-by":"publisher","first-page":"2092","DOI":"10.1007\/s00125-009-1456-y","volume":"52","author":"B de Lauzon-Guillain","year":"2009","unstructured":"de Lauzon-Guillain B, Fournier A, Fabre A et al (2009) Menopausal hormone therapy and new-onset diabetes in the French Etude Epidemiologique de Femmes de la Mutuelle Generale de l\u2019Education Nationale (E3N) cohort. Diabetologia 52(10):2092\u20132100. https:\/\/doi.org\/10.1007\/s00125-009-1456-y","journal-title":"Diabetologia"},{"issue":"13","key":"6856_CR58","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1001\/jama.2013.278040","volume":"310","author":"JE Manson","year":"2013","unstructured":"Manson JE, Chlebowski RT, Stefanick ML et al (2013) Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women\u2019s Health Initiative randomized trials. JAMA 310(13):1353\u20131368. https:\/\/doi.org\/10.1001\/jama.2013.278040","journal-title":"JAMA"},{"issue":"4","key":"6856_CR59","doi-asserted-by":"publisher","first-page":"249","DOI":"10.7326\/M14-0353","volume":"161","author":"SM Harman","year":"2014","unstructured":"Harman SM, Black DM, Naftolin F et al (2014) Arterial imaging outcomes and cardiovascular risk factors in recently menopausal women: a randomized trial. Ann Intern Med 161(4):249\u2013260. https:\/\/doi.org\/10.7326\/M14-0353","journal-title":"Ann Intern Med"},{"issue":"12","key":"6856_CR60","doi-asserted-by":"publisher","first-page":"4456","DOI":"10.1210\/jc.2015-3084","volume":"100","author":"RI Pereira","year":"2015","unstructured":"Pereira RI, Casey BA, Swibas TA, Erickson CB, Wolfe P, Van Pelt RE (2015) Timing of estradiol treatment after menopause may determine benefit or harm to insulin action. J Clin Endocrinol Metab 100(12):4456\u20134462. https:\/\/doi.org\/10.1210\/jc.2015-3084","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"6856_CR61","doi-asserted-by":"publisher","first-page":"83","DOI":"10.3889\/oamjms.2016.024","volume":"4","author":"I Bitoska","year":"2016","unstructured":"Bitoska I, Krstevska B, Milenkovic T et al (2016) Effects of hormone replacement therapy on insulin resistance in postmenopausal diabetic women. Open Access Maced J Med Sci 4(1):83\u201388. https:\/\/doi.org\/10.3889\/oamjms.2016.024","journal-title":"Open Access Maced J Med Sci"},{"key":"6856_CR62","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.maturitas.2016.06.020","volume":"91","author":"IA Ebong","year":"2016","unstructured":"Ebong IA, Watson KE, Hairston KG et al (2016) Body fat distribution, menopausal hormone therapy and incident type 2 diabetes in postmenopausal women of the MESA study. Maturitas 91:147\u2013152. https:\/\/doi.org\/10.1016\/j.maturitas.2016.06.020","journal-title":"Maturitas"},{"issue":"11","key":"6856_CR63","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1097\/GME.0000000000001848","volume":"28","author":"JE Kim","year":"2021","unstructured":"Kim JE, Choi J, Park J, Shin A, Choi NK, Choi JY (2021) Effects of menopausal hormone therapy on cardiovascular diseases and type 2 diabetes in middle-aged postmenopausal women: analysis of the Korea National Health Insurance Service Database. Menopause 28(11):1225\u20131232. https:\/\/doi.org\/10.1097\/GME.0000000000001848","journal-title":"Menopause"},{"issue":"1","key":"6856_CR64","doi-asserted-by":"publisher","first-page":"e28361","DOI":"10.1097\/MD.0000000000028361","volume":"101","author":"T Qi","year":"2022","unstructured":"Qi T, Wang X, Huang Y et al (2022) Change in metabolic parameters and reproductive hormones from baseline to 6-month hormone therapy. Medicine (Baltimore) 101(1):e28361. https:\/\/doi.org\/10.1097\/MD.0000000000028361","journal-title":"Medicine (Baltimore)"},{"issue":"5","key":"6856_CR65","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1097\/GME.0000000000002170","volume":"30","author":"JS Yuk","year":"2023","unstructured":"Yuk JS, Kim JM (2023) Menopausal hormone therapy and the risk of type 2 diabetes mellitus: Health Insurance Database in South Korea-based retrospective cohort study. Menopause 30(5):497\u2013505. https:\/\/doi.org\/10.1097\/GME.0000000000002170","journal-title":"Menopause"},{"issue":"2","key":"6856_CR66","doi-asserted-by":"publisher","first-page":"727","DOI":"10.3233\/JAD-221240","volume":"93","author":"VJ Williams","year":"2023","unstructured":"Williams VJ, Koscik R, Sicinski K, Johnson SC, Herd P, Asthana S (2023) Associations between midlife menopausal hormone therapy use, incident diabetes, and late life memory in the Wisconsin Longitudinal Study. J Alzheimers Dis 93(2):727\u2013741. https:\/\/doi.org\/10.3233\/JAD-221240","journal-title":"J Alzheimers Dis"},{"issue":"4","key":"6856_CR67","doi-asserted-by":"publisher","first-page":"101546","DOI":"10.1016\/j.diabet.2024.101546","volume":"50","author":"YH Shih","year":"2024","unstructured":"Shih YH, Yang CY, Wang SJ, Lung CC (2024) Menopausal hormone therapy decreases the likelihood of diabetes development in peri-menopausal individuals with prediabetes. Diabetes Metab 50(4):101546. https:\/\/doi.org\/10.1016\/j.diabet.2024.101546","journal-title":"Diabetes Metab"},{"issue":"2","key":"6856_CR68","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1111\/cen.15253","volume":"103","author":"Q Ouyang","year":"2025","unstructured":"Ouyang Q, Dong Y, Li R et al (2025) Associations of hysterectomy, oophorectomy, and hormone replacement therapy with the risk of type 2 diabetes mellitus in postmenopausal women. Clin Endocrinol (Oxf) 103(2):167\u2013176. https:\/\/doi.org\/10.1111\/cen.15253","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"7","key":"6856_CR69","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1016\/j.kjms.2014.03.002","volume":"30","author":"Y Xu","year":"2014","unstructured":"Xu Y, Lin J, Wang S, Xiong J, Zhu Q (2014) Combined estrogen replacement therapy on metabolic control in postmenopausal women with diabetes mellitus. Kaohsiung J Med Sci 30(7):350\u2013361. https:\/\/doi.org\/10.1016\/j.kjms.2014.03.002","journal-title":"Kaohsiung J Med Sci"},{"issue":"3","key":"6856_CR70","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/0026-0495(95)90168-x","volume":"44","author":"OL Svendsen","year":"1995","unstructured":"Svendsen OL, Hassager C, Christiansen C (1995) Age- and menopause-associated variations in body composition and fat distribution in healthy women as measured by dual-energy X-ray absorptiometry. Metabolism 44(3):369\u2013373. https:\/\/doi.org\/10.1016\/0026-0495(95)90168-x","journal-title":"Metabolism"},{"issue":"3","key":"6856_CR71","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1210\/er.2016-1146","volume":"38","author":"F Mauvais-Jarvis","year":"2017","unstructured":"Mauvais-Jarvis F, Manson JE, Stevenson JC, Fonseca VA (2017) Menopausal hormone therapy and type 2 diabetes prevention: evidence, mechanisms, and clinical implications. Endocr Rev 38(3):173\u2013188. https:\/\/doi.org\/10.1210\/er.2016-1146","journal-title":"Endocr Rev"},{"key":"6856_CR72","doi-asserted-by":"publisher","unstructured":"Xiao Z, Liu H (2024) The estrogen receptor and metabolism. Women's Health 20:17455057241227362. https:\/\/doi.org\/10.1177\/17455057241227362","DOI":"10.1177\/17455057241227362"},{"issue":"1\u20133","key":"6856_CR73","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.jsbmb.2010.06.012","volume":"122","author":"A Foryst-Ludwig","year":"2010","unstructured":"Foryst-Ludwig A, Kintscher U (2010) Metabolic impact of estrogen signalling through ERalpha and ERbeta. J Steroid Biochem Mol Biol 122(1\u20133):74\u201381. https:\/\/doi.org\/10.1016\/j.jsbmb.2010.06.012","journal-title":"J Steroid Biochem Mol Biol"},{"key":"6856_CR74","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.molmet.2018.05.008","volume":"15","author":"BT Palmisano","year":"2018","unstructured":"Palmisano BT, Zhu L, Eckel RH, Stafford JM (2018) Sex differences in lipid and lipoprotein metabolism. Mol Metab 15:45\u201355. https:\/\/doi.org\/10.1016\/j.molmet.2018.05.008","journal-title":"Mol Metab"},{"issue":"1","key":"6856_CR75","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1161\/HYPERTENSIONAHA.108.120022","volume":"54","author":"M Barton","year":"2009","unstructured":"Barton M, Meyer MR (2009) Postmenopausal hypertension: mechanisms and therapy. Hypertension 54(1):11\u201318. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.108.120022","journal-title":"Hypertension"},{"issue":"4","key":"6856_CR76","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1161\/HYPERTENSIONAHA.107.105742","volume":"51","author":"M Coylewright","year":"2008","unstructured":"Coylewright M, Reckelhoff JF, Ouyang P (2008) Menopause and hypertension: an age-old debate. Hypertension 51(4):952\u2013959. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.107.105742","journal-title":"Hypertension"},{"key":"6856_CR77","doi-asserted-by":"publisher","unstructured":"\"The 2022 Hormone Therapy Position Statement of The North American Menopause Society\" Advisory Panel (2022) The 2022 hormone therapy position statement of The North American Menopause Society. Menopause 29(7): 767-794. https:\/\/doi.org\/10.1097\/GME.0000000000002028","DOI":"10.1097\/GME.0000000000002028"},{"issue":"2","key":"6856_CR78","doi-asserted-by":"publisher","first-page":"69","DOI":"10.6118\/jmm.20000","volume":"26","author":"SR Lee","year":"2020","unstructured":"Academic Committee of the Korean Society of Menopause, Lee SR, Cho MK et al (2020) The 2020 menopausal hormone therapy guidelines. J Menopausal Med 26(2):69\u201398. https:\/\/doi.org\/10.6118\/jmm.20000","journal-title":"J Menopausal Med"},{"key":"6856_CR79","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.maturitas.2018.08.009","volume":"117","author":"R Slopien","year":"2018","unstructured":"Slopien R, Wender-Ozegowska E, Rogowicz-Frontczak A et al (2018) Menopause and diabetes: EMAS clinical guide. Maturitas 117:6\u201310. https:\/\/doi.org\/10.1016\/j.maturitas.2018.08.009","journal-title":"Maturitas"},{"issue":"8","key":"6856_CR80","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1111\/jog.13684","volume":"44","author":"H Okano","year":"2018","unstructured":"Okano H, Higuchi T, Kurabayashi T et al (2018) Japan Society of Obstetrics and Gynecology and Japan Society for Menopause and Women\u2019s Health 2017 guidelines for hormone replacement therapy. J Obstet Gynaecol Res 44(8):1355\u20131368. https:\/\/doi.org\/10.1111\/jog.13684","journal-title":"J Obstet Gynaecol Res"},{"issue":"5","key":"6856_CR81","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1080\/13697137.2024.2394950","volume":"27","author":"N Panay","year":"2024","unstructured":"Panay N, Ang SB, Cheshire R et al (2024) Menopause and MHT in 2024: addressing the key controversies - an International Menopause Society White Paper. Climacteric 27(5):441\u2013457. https:\/\/doi.org\/10.1080\/13697137.2024.2394950","journal-title":"Climacteric"},{"issue":"11","key":"6856_CR82","doi-asserted-by":"publisher","first-page":"3975","DOI":"10.1210\/jc.2015-2236","volume":"100","author":"CA Stuenkel","year":"2015","unstructured":"Stuenkel CA, Davis SR, Gompel A et al (2015) Treatment of symptoms of the menopause: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 100(11):3975\u20134011. https:\/\/doi.org\/10.1210\/jc.2015-2236","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"6856_CR83","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1007\/s00404-020-05682-4","volume":"302","author":"O Ortmann","year":"2020","unstructured":"Ortmann O, Beckermann MJ, Inwald EC et al (2020) Peri- and postmenopause-diagnosis and interventions interdisciplinary S3 guideline of the association of the scientific medical societies in Germany (AWMF 015\/062): short version. Arch Gynecol Obstet 302(3):763\u2013777. https:\/\/doi.org\/10.1007\/s00404-020-05682-4","journal-title":"Arch Gynecol Obstet"},{"key":"6856_CR84","unstructured":"Australasian Menopause Society (2021) Risks and benefits of MHT. Available from https:\/\/menopause.org.au\/hp\/information-sheets\/risks-and-benefits-of-mht-hrt. Accessed 16\/11\/2025"},{"key":"6856_CR85","unstructured":"National Institute for Health and Care Excellence (2024) Menopause: identification and management. Available from https:\/\/www.nice.org.uk\/guidance\/ng23. Accessed 16\/11\/2025"},{"key":"6856_CR86","unstructured":"The Royal Australian and New Zealand College of Obstetrician and Gynaecologists (2020) Managing menopausal symptoms. Available from https:\/\/ranzcog.edu.au\/wp-content\/uploads\/Managing-Menopausal-Symptoms.pdf. Accessed 16\/11\/2025"},{"key":"6856_CR87","unstructured":"Royal Australian College of General Practitioners (2025) Guidelines for preventive activities in general practice. Available from https:\/\/www.racgp.org.au\/getattacxhment\/9755764e-25f8-4799-bbca-29ddaf8c6d65\/Guidelines-for-preventive-activities-in-general-practice.aspx. Accessed 16\/11\/2025"},{"issue":"1","key":"6856_CR88","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.maturitas.2005.02.011","volume":"51","author":"P Kenemans","year":"2005","unstructured":"Kenemans P, Speroff L, International Tibolone Consensus Group (2005) Tibolone: clinical recommendations and practical guidelines. A report of the International Tibolone Consensus Group. Maturitas 51(1):21\u201328. https:\/\/doi.org\/10.1016\/j.maturitas.2005.02.011","journal-title":"Maturitas"},{"key":"6856_CR89","unstructured":"Australasian Menopause Society (2025) Tibolone as menopausal hormone therapy. Available from https:\/\/menopause.org.au\/hp\/information-sheets\/tibolone-as-menopausal-hormone-therapy. Accessed 16\/11\/2025"}],"container-title":["Diabetologia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00125-026-06856-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00125-026-06856-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00125-026-06856-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T11:13:11Z","timestamp":1789729991000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00125-026-06856-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,18]]},"references-count":89,"alternative-id":["6856"],"URL":"https:\/\/doi.org\/10.1007\/s00125-026-06856-6","relation":{},"ISSN":["0012-186X","1432-0428"],"issn-type":[{"value":"0012-186X","type":"print"},{"value":"1432-0428","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,18]]},"assertion":[{"value":"14 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The datasets generated and\/or analysed during the present study are available from the corresponding author. Access will be granted to qualified researchers for non-commercial research purposes, subject to approval by the corresponding author and, where applicable, institutional guidelines. Requests should include a brief description of the proposed research and analysis plan. There are no time restrictions on availability.","order":1,"name":"Ethics","label":"Data availability","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"Open Access funding enabled and organized by CAUL and its Member Institutions. This work was supported by a National Health and Medical Research Council investigator grant (APP2009577). The study funder was not involved in the design of the study, in the collection, analysis or interpretation of the data or in the writing of the report and did not impose any restrictions regarding the publication of the report.","order":2,"name":"Ethics","label":"Funding","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"The authors declare that there are no relationships or activities that might bias, or be perceived to bias, their work.","order":3,"name":"Ethics","label":"Authors\u2019 relationships and activities","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"CL, AJD and GDM were responsible for the concept and design of the study. AJD and GDM supervised the study. CL and AJD contributed to data acquisition. CL carried out data analysis, interpretation and drafting of the manuscript. JD provided clinical interpretation. LWR conducted process verification. All authors revised the manuscript critically and approved the final version. GDM had full access to the data and takes responsibility for the integrity of the data and accuracy of the analysis.","order":4,"name":"Ethics","label":"Contribution statement","group":{"name":"EthicsHeading","label":"Ethics"}}]}}